Capivasertib, a novel AKT inhibitor, has gained approval as a second-line therapy for advanced breast cancer, but its high cost has sparked concerns about ...
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.